NO20012214L - Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller - Google Patents

Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller

Info

Publication number
NO20012214L
NO20012214L NO20012214A NO20012214A NO20012214L NO 20012214 L NO20012214 L NO 20012214L NO 20012214 A NO20012214 A NO 20012214A NO 20012214 A NO20012214 A NO 20012214A NO 20012214 L NO20012214 L NO 20012214L
Authority
NO
Norway
Prior art keywords
sertoli cells
biological factor
creation
preparation
genetically modified
Prior art date
Application number
NO20012214A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012214D0 (no
Inventor
Shaun A Kirkpatrick
Original Assignee
Shaun A Kirkpatrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaun A Kirkpatrick filed Critical Shaun A Kirkpatrick
Publication of NO20012214D0 publication Critical patent/NO20012214D0/no
Publication of NO20012214L publication Critical patent/NO20012214L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20012214A 1998-11-06 2001-05-04 Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller NO20012214L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10743898P 1998-11-06 1998-11-06
PCT/US1999/026072 WO2000027409A1 (en) 1998-11-06 1999-11-04 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells

Publications (2)

Publication Number Publication Date
NO20012214D0 NO20012214D0 (no) 2001-05-04
NO20012214L true NO20012214L (no) 2001-07-06

Family

ID=22316637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012214A NO20012214L (no) 1998-11-06 2001-05-04 Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller

Country Status (10)

Country Link
EP (1) EP1126858B1 (de)
JP (1) JP5323293B2 (de)
AT (1) ATE452643T1 (de)
AU (1) AU767763B2 (de)
CA (1) CA2349475C (de)
DE (1) DE69941849D1 (de)
DK (1) DK1126858T3 (de)
ES (1) ES2338076T3 (de)
NO (1) NO20012214L (de)
WO (1) WO2000027409A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
DE60128130T2 (de) * 2000-11-03 2007-12-27 Zymogenetics, Inc., Seattle Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725854A (en) * 1994-04-13 1998-03-10 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells an allografts or xenografts
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease

Also Published As

Publication number Publication date
ES2338076T3 (es) 2010-05-03
AU1813200A (en) 2000-05-29
JP2002529419A (ja) 2002-09-10
CA2349475A1 (en) 2000-05-18
AU767763B2 (en) 2003-11-20
DE69941849D1 (de) 2010-02-04
ATE452643T1 (de) 2010-01-15
EP1126858B1 (de) 2009-12-23
CA2349475C (en) 2010-01-05
NO20012214D0 (no) 2001-05-04
DK1126858T3 (da) 2010-03-01
JP5323293B2 (ja) 2013-10-23
WO2000027409A1 (en) 2000-05-18
EP1126858A4 (de) 2004-06-30
EP1126858A1 (de) 2001-08-29

Similar Documents

Publication Publication Date Title
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
PL322015A1 (en) Derivatives of hydroxylamine useful as compounds enhancing production of accompanying molecular protein and ethod of obtaining them
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
AU6331898A (en) Forskohlin for promoting lean body mass
DE69731540D1 (de) Behandlung von diarrhoe
DK58789A (da) Proteiner med faktor viii-aktivitet, fremgangsmaade til deres fremstilling ved anvendelse af genetisk konstruerede celler og farmaceutiske kompositioner indeholdende proteinerne
BR9608114A (pt) Vacinas de pertussis a celular e processos para preparação das mesmas
ATE218154T1 (de) Physikalisch modifizierte abbaubare thermoplastische zusammensetzung
ATE526818T1 (de) Gentechnisch hergestellte wasserlinse
GB2301363A (en) Human phosphodiesterase type ivc and its production and use
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
IL196900A (en) Autologous T cell vaccine compositions
PT1318198E (pt) Processo para produzir um polipeptido recombinante que envolve a adicao de um inibidor de quimotripsina ao meio de cultura celular
DE69637709D1 (de) Durch elektroporation vermittelter molekulartransfer in intakten pflanzen
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
BR9707994A (pt) Adenovírus recombinantes defectivo composição farmacêutica utilização do adenovirus composição e processo de preparação de células t citotóxicas especificas de um antigene tumoral
NZ334568A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
NO20012214L (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
EP2281892A3 (de) Verfahren zur Herstellung von Polypeptiden in atmungsdefizienten Trichoderma Zellen
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
RU95101019A (ru) Способ получения фактора некроза опухоли, фактор некроза опухоли, днк, клетка, композиция
WO1997023607A3 (en) Presentation of antigen, introduced into cells by stimulation of macropinocytosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application